21st Jan 2021 13:20
Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Sees "highly positive" data for SFX-01 in pre-clinical models of glioma and glioblastoma, which are types of brain tumours. Says data shows tumour shrinkage and significantly extended survival times, adding SFX-01 also substantially increases the therapeutic effect of radiotherapy.
Evgen Pharma notes it plans to expand upon the pre-clinical data and start the process of designing a Phase 2 clinical trial.
Current stock price: 11.12 pence
Year-to-date change: up 7.4%
By Ife Taiwo; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L